충북대학교 종양연구소에서 다음과 같이 초청세미나를 개최하오니 많은 참여 부탁드립니다.
- 다 음 -
1. 연 자 : 박 기 랑 교수 (충북보건과학대학교)
2. 일 시 : 2020년 12월 11일 (금) 오후 5시
3. 연 제 : Gene therapy involves the modification of the genetic material of living cell
4. 장 소 : 종양연구소 세미나실 104호
5. 발 표 내 용
Gene therapy involves the modification of the genetic material of living cell
Gene therapy involves the modification of the genetic material of living cells to perform medical interventions that may be therapeutic or prophylactic in nature. These modifications may be effected in vivo through direct genetic manipulation, or ex vivo on cells that are administered to the patient as a form of somatic cell therapy. Gene therapy development has been pursued for many conditions, including cancers, vascular diseases, infectious diseases, and genetic disorders.
Since 1990, when the first gene therapeutic clinical trial was performed in the USA for ACA-SCID, 3001 subsequent clinical trials have been initiated worldwide. Beginning with Glybera in 2012, an additional seven in vivo and ex vivo gene therapy products have received commercial regulatory approval by the FDA and/or EMA. With recent additions Kymriah and Yescarta, CAR-T therapies that represent a novel product type, gene therapy as a technology shows great promise for additionally developing potential blockbuster drugs.
Success in commercialization of gene therapeutic drug development has been greatly related to the optimized strategies of gene expression package and delivery viral vectors, and also to utilizing the qualified outsourcing organizations.